Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. [electronic resource]
Producer: 20171211Description: 355ra116 p. digitalISSN:- 1946-6242
- Adult
- Aged
- Biomarkers, Tumor -- metabolism
- CD4-Positive T-Lymphocytes -- immunology
- CD8-Positive T-Lymphocytes -- immunology
- Cell Proliferation
- Cyclophosphamide -- pharmacology
- Female
- Humans
- Immunotherapy -- adverse effects
- Lymphocyte Depletion
- Lymphocyte Subsets -- immunology
- Lymphoma, Non-Hodgkin -- drug therapy
- Male
- Middle Aged
- Receptors, Antigen, T-Cell -- immunology
- Syndrome
- Transgenes
- Treatment Outcome
- Vidarabine -- analogs & derivatives
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.